不同时间服用比索洛尔对非杓犁高衄压缸压的影响

目的：观察不同给药时间分别给予比索洛尔对非杓型原发性高血压患者的降压疗效和血压节律恢复的影响。方法：选取60例非杓型高血压患者,采取随机平行对照试验,观察比索洛尔（n=30）每日早晨（8：00）给药2．5—10mg、比索洛尔（n=30）每日夜间（20：00）给药2．5—10mg治疗8周后的降压疗效。结果：两种给药方法均能降低非杓型高血压患者的全天血压（P〈0．05）。两种给药方法在白天的血压控制上无显著性差异（P〉0．05）,但在夜间血压的控制上夜间服药降压效果具有显著性差异（P〈0．05）。夜间服药在血压节律恢复方面优于早晨服药（P〈0．05）,早晨服药组有10例恢复杓型,夜间服药组有19例恢复杓型。结论：比索洛尔的两种给药方式均能安全有效的降压,但对于非杓型高血压患者夜间服药优于早晨服药,更有利于血压节律的恢复。     

氨氯地平、比索洛尔对高血压合并心绞痛患者CAP及IMT 的影响

目的:比较氨氯地平、比索洛尔对高血压合并心绞痛患者中心动脉压(central artery pressure,CAP)及颈动脉内中膜厚度(intima-media thickness,IMT)的影响。方法:选择我院2013年8月-2014年9月收治的高血压合并心绞痛患者76例,随机分为观察组和对照组,各38例。观察组给予氨氯地平5 mg/d,对照组给予比索洛尔2.5 mg/d,疗程均为1年。测定并对比两组治疗前后血压、CAP、IMT变化情况以及心绞痛的治疗效果。结果:观察组治疗后CAP收缩压、舒张压、IMT分别为(130.36±5.09)mm Hg、(73.38±5.76)mm Hg、(0.89±0.08)mm,均明显低于对照组的(144.82±6.54)mm Hg、(84.89±6.14)mm Hg、(1.01±0.12)mm,差异均有统计学意义(P0.05)。观察组治疗总有效率为89.47%,高于对照组的76.32%,但差异无统计学意义(P0.05)。结论:氨氯地平与比索洛尔治疗高血压合并心绞痛的临床疗效相当,但氨氯地平在降低高血压合并心绞痛患者CAP、IMT方面的效果优于比索洛尔。     

芪苈强心胶囊联合比索洛尔对老年心力衰竭患者的疗效

目的:研究芪苈强心胶囊联合比索洛尔对老年心力衰竭患者的临床疗效。方法:选择2015年6月~2016年6月在我院进行诊治的老年心力衰竭患者126例,随机分为两组,对照组给予芪苈强心胶囊,观察组在对照组基础上加用比索洛尔。治疗3个月后,比较两组的疗效,以及治疗前后的血压、心率、6 min步行最大距离、脑钠肽水平;采用超声心动图检测两组的左心室舒张末期容积、左心室射血分数、左心室短轴缩短率和左心室收缩末期容积。结果:观察组的有效率为92.06%(58/63),明显高于对照组的73.02%(46/63)(P0.05);治疗后两组血压无明显变化(P0.05),心率和脑钠肽水平明显降低(P0.05),6 min步行最大距离明显增加(P0.05),且观察组明显优于对照组(P0.05);两组的左心室射血分数明显降低(P0.05),左心室舒张末期容积、左心室短轴缩短率和左心室收缩末期容积明显升高(P0.05),且观察组明显优于对照组(P0.05)。结论:芪苈强心胶囊联合比索洛尔能有效改善老年心力衰竭患者的心功能,具有较好的临床疗效。     

原发性高血压患者血压昼夜节律与靶器官损害的关系研究

目的:研究原发性高血压患者血压昼夜节律异常是否与靶器官损害存在关联。方法:将2015年2~11月份在我院治疗的94例原发性高血压病人按照血压昼夜节律是否正常分为节律正常组52例和异常组42例。比较两组患者的24h、白天、夜间的收缩压(SBP)与舒张压(DBP)及血压负荷,并且比较两组患者心脏、脑、肾损伤相关指标。结果:异常组全天24h、白天、夜间SBP及DBP,血压负荷均高于正常组,差异具有统计学意义(P0.05)。异常组患者左室重量(LVM)和左室重量指数(LVMI)、发生心肌缺血次数及持续时间、发生脑梗死几率均明显高于正常组,差异有统计学意义(P0.05)。异常组尿微量白蛋白(MAU)、尿酸(UA)水平均高于正常组,差异有统计学意义(P0.05)。结论:原发性高血压患者出现昼夜节律异常,可能对相关靶器官造成损伤。     

比索洛尔联合丹红注射液治疗老年心肌缺血的临床疗效

目的:探讨比索洛尔联合丹红注射液对老年心肌缺血患者血清肌钙蛋白、心肌酶水平及临床疗效的影响。方法:收集我院收治的老年心肌缺血患者58例,随机分为观察组和对照组,每组各29例。所有患者均给予调脂、抗血小板和抗心肌缺血等基础治疗。对照组患者给予丹红注射液静脉滴注,观察组在对照组基础上给予比索洛尔治疗。观察并比较两组患者治疗前后的心肌酶(CK、CK-MB、AST、LDH)、血清肌钙蛋白I(c Tn I)、肿瘤坏死因子-α(TNF-α)水平及临床疗效。结果:与治疗前相比,两组患者治疗后心肌酶(CK、CK-MB、AST、LDH)、血清肌钙蛋白I(c Tn I)及肿瘤坏死因子-α(TNF-α)水平降低(P0.05);与对照组比较,观察组患者心肌酶(CK、CK-MB、AST、LDH)、血清肌钙蛋白I(c Tn I)及肿瘤坏死因子-α(TNF-α)水平较低(P0.05),临床总有效率较高(P0.05)。结论:比索洛尔联合丹红注射液对老年心肌缺血有较好的临床疗效。     

2型糖尿病合并原发性高血压患者动态血压昼夜节律的研究

目的:探讨观察2型糖尿病(T2DM)合并原发性高血压患者动态血压昼夜节律的的变化。方法:采用动态血压监测(ABPM)仪,测定50例T2DM合并原发性高血压患者(观察组)和原发性高血压患者(对照组)的24h血压、日间血压及夜间血压,计算血压昼夜差值。结果:观察组24h血压平均值、日间血压平均值、夜间血压平均值及血压昼夜差值均显著高于对照组,相比较均有显著性差性(P0.05)。结论:T2DM合并原发性高血压时对患者的昼夜血压调节功能损害较大。改善T2DM合并原发性高血压患者体内糖代谢状况,可能有助于改善T2DM合并原发性高血压患者心血管系统血流动力学,从而减少心血管并发症。     

无左室肥厚的非杓型高血压患者血清GDF-15、YKL-40水平表达及其临床意义

摘要 目的：探讨无左室肥厚（NLVH）的非杓型高血压患者血清生长分化因子15（GDF-15）、人软骨糖蛋白39（YKL-40）水平的表达及其临床意义。方法：选取2019年6月至2020年6月张家口学院附属人民医院收治的NLVH原发性高血压患者104例为研究对象,根据夜间收缩压下降率（SBPF）将其分为非杓型组（SBPF＜10%,n=60）和杓型组（10%≤SBPF≤20%,n=44）。另选取同期于张家口学院附属人民医院进行体检的健康志愿者49例记为对照组。比较三组受试者的血清GDF-15、YKL-40水平,比较非杓型和杓型NLVH患者的舒张压、收缩压、颈动脉内膜中层厚度（IMT）值、僵硬度、紧张度和扩张性、超声心动图参数、血压昼夜节律指标,分析NLVH的非杓型高血压患者血清GDF-15、YKL-40水平与超声心动图参数、血压昼夜节律、颈动脉粥样硬化指标的相关性。采用多元线性逐步回归分析非杓型高血压发病的影响因素。结果：非杓型NLVH组和杓型NLVH组患者的血清GDF-15、YKL-40水平均高于对照组患者,且非杓型NLVH组高于杓型NLVH组（P<0.05）;与杓型NLVH组患者比较,非杓型NLVH组患者的IMT、僵硬度、夜间平均收缩压（nSBP）、平均舒张压（nDBP）、左室舒张末期内径（LVEDD）、左房内径（LAD）、室间隔厚度（LVSD）、左室后壁厚度（PWD）均升高,LVEF、紧张度、扩张性则降低（P<0.05）,但两组患者的白天平均收缩压（dSBP）、白天平均舒张压（dDBP）比较差异无统计学意义（P>0.05）。经Pearson相关性分析显示,NLVH的非杓型高血压患者的血清GDF-15、YKL-40水平与IMT、僵硬度、LAD、LVEDD、LVSD、PWD、nSBP、nDBP呈正相关,与LVEF、紧张度、扩张性呈负相关（P<0.05）,而与dSBP、dDBP无明显相关性（P>0.05）;GDF-15与YKL-40水平呈正相关（P<0.05）。多元线性逐步回归分析显示：颈动脉IMT、僵硬度、LAD、LVEDD、nSBP、nDBP、LVEF、颈动脉紧张度、GDF-15是非杓型高血压发病的独立影响因素（P<0.05）。结论：NLVH的非杓型高血压患者血清GDF-15、YKL-40水平异常升高,且与超声心动图参数、血压昼夜节律、颈动脉粥样硬化具有一定关联,患者发病受多种因素影响,临床工作中应结合相关因素对患者进行适当干预。     

褪黑素对人体睡眠和血压的影响

昼夜节律遵循体内的生物钟规律,调节着机体多种功能和代谢过程,如血压、睡眠周期和体温等,睡眠周期表现出明显的昼夜节律,血压的变化也遵循24小时昼夜模式.研究表明,昼夜节律异常是睡眠障碍和心血管疾病的危险诱因之一.昼夜节律的起搏点受褪黑素的调节,而褪黑素的合成和分泌也具有昼夜节律性.内源性褪黑素可以通过多种方式增强人类节律系统的功能,外源性褪黑素作为一种时相药,可以对人体昼夜节律紊乱产生调节作用.越来越多的研究发现,褪黑素与睡眠和血压的变化有紧密的联系,深入研究褪黑素在其中的作用有利于阐明该类疾病的发生机制.本文旨在就褪黑素对人体睡眠和血压的影响作一综述.     

高血压不同并发症患者动态血压特点分析

目的:探讨高血压不同并发症患者动态血压特点。方法:选取123例确诊为高血压病的患者,根据合并不同的并发症分为四组,即单纯高血压(EH)组、高血压合并心房颤动(EH-AF)组、高血压合并腔隙性脑梗死(EH-LI)组和高血压合并左室肥厚(EH-LVH)组,行24H动态血压监测,分析动态血压各参数的变化。结果:合并有各种并发症的原发性高血压患者,其3级高血压所占百分比明显高于单纯原发性高血压,其平均收缩压和平均舒张压及收缩压、舒张压负荷值及血压昼夜波动节律异常均高于单纯原发性高血压患者;高血压合并左室肥厚患者,与高血压合并心房颤动及腔隙性脑梗死患者比较,平均收缩压和平均舒张压及收缩压、舒张压负荷值及血压昼夜波动节律异常均升高。结论:血压水平、血压负荷及血压昼夜波动节律异常与高血压并发症密切相关;高血压病合并不同并发症,其动态血压参数有不同特点。     

富马酸比索洛尔对老年慢性心力衰竭患者血清胆红素、NT-proBNP及运动耐力的影响

摘要 目的：探究富马酸比索洛尔对老年慢性心力衰竭患者血清胆红素、N-末端B型利钠肽原（N-Terminal pro-brain natriuretic peptide,NT-proBNP）及运动耐力的影响。方法：选择我院于2017年1月~2020年1月收治的老年慢性心力衰竭患者80例,根据入院顺序经随机数字表法分成两组,对照组40例患者仅采用常规治疗方案进行治疗,研究组40例患者在常规治疗基础上联合富马酸比索洛尔进行治疗。对比两组患者治疗总有效率、左心室射血分数（left ventricular ejection fraction,LVEF）、心排量（cardiac output,CO）、每搏输出量（stroke volume,SV）、血清 NT-proBNP水平、6 min 步行测试距离、总胆红素、直接胆红素水平。结果：研究组的治疗总有效率90.00 %,显著高于对照组72.50 %（P＜0.05）; 治疗前,两组的LVEF、CO、SV水平对比无差异（P＞0.05）;治疗后,两组的LVEF、CO、SV水平均升高,且研究组更高（P＜0.05）;治疗前,两组的NT-proBNP水平及6 min 步行测试距离对比无显著性差异（P＞0.05）;治疗后,两组的NT-proBNP水平比治疗前均显著降低、6 min 步行测试距离比治疗前均显著升高,且研究组更优（P＜0.05）;治疗前,两组的总胆红素、直接胆红素水平对比无差异（P＞0.05）;治疗后,两组的总胆红素、直接胆红素水平均比治疗前显著降低,且研究组显著低于对照组（P＜0.05）。结论：在常规治疗基础上联合富马酸比索洛尔治疗老年慢性心力衰竭的临床效果显著,其可有效改善患者心功能及运动耐力,值得推荐至临床广泛应用。     

Wrist Skin Temperature,Motor Activity,and Body Position as Determinants of the Circadian Pattern of Blood Pressure

Although the circadian blood pressure (BP) pattern has been extensively studied, the determinants of this rhythm are not fully understood. Peripheral vasodilatation is a regulatory mechanism for BP maintenance. However, it remains to be established whether the increase of nocturnal distal skin temperature associated with heat loss could also reflect the dipping status. For the first time, this paper investigates the relationship between BP and skin wrist temperature (WT), to evaluate whether the WT circadian rhythm can serve as screening procedure to detect dipping/non-dipping BP patterns. In addition, the authors compare the relationship between WT and other variables previously described as determinants of the BP pattern, such as physical activity and body position. Measurements of WT, motor activity, and body position for 5 d, plus ambulatory BP for 24-h during that span, were obtained from 28 diurnally active normotensive volunteers. WT was negatively correlated, whereas activity and body position were positively correlated, with systolic and diastolic BPs. However, these relationships were stronger during the rest than activity phase. In addition, a 78.6% concordance was detected between the observed dips in BP and the predicted BP pattern calculated based on the WT rhythm. Thus, these results suggest that the increase in WT produced by heat loss during the rest phase through peripheral skin blood vessels is the result of blood vessel vasodilatation reflexes in response to a shift from a standing to a supine position, together with shift in the circadian sympathetic/parasympathetic balance (nocturnal parasympathetic activation). In conclusion, WT could be considered as a potential new screening procedure to implement the diagnosis of non-dipping BP pattern. (Author correspondence: angerol@um.es)     

Comparison of the Efficacy of Morning versus Evening Administration of Olmesartan in Uncomplicated Essential Hypertension

A total of 18 diurnally active subjects with uncomplicated, mild to moderate, essential hypertension were studied to compare the efficacy of the morning versus evening administration of an oral olmesartan medication. After a two‐week, wash‐out/placebo run‐in period, subjects with clinic diastolic blood pressure (DBP) ≥90 mm Hg and <110 mm Hg began 12 weeks of 20 mg olmesartan medoxomil tablet therapy at 08:00 h daily. Four of the 18 subjects required dose escalation to 40 mg at eight weeks because of clinic DBP≥90 mm Hg. After the 12‐week period of once‐a‐day 08:00 h treatment, subjects were immediately switched to an evening (20:00 h) drug‐ingestion schedule for another 12‐week period without change in dose. Subjects underwent 24 h ambulatory blood pressure monitoring (ABPM) before the initiation of morning treatment and at the end of both the 12‐week morning and evening treatment arms. Dosing time did not exert statistically significant differences on the efficacy of olmesartan: the reduction from baseline in the 24 h mean systolic (SBP) and DBP was, respectively, 18.8 and 14.6 mm Hg with morning dosing and 16.1 and 13.2 mm Hg with evening dosing (p>0.152 between groups). The amplitude of the BP 24 h pattern did not vary with dosing time, indicating full 24 h BP reduction no matter the clock hour of treatment. Although, the BP‐lowering effect was somewhat better with morning dosing, the results of this study suggest that the studied olmesartan medoxomil preparation efficiently reduces BP when ingested in the morning (08:00 h) or evening (20:00 h) in equivalent manner, based on statistical testing, throughout the 24 h.     

Effects of Diet and Time of the Day on Serum and CSF Leptin Levels in Osborne‐Mendel and S5B/Pl Rats

Objective: To characterize the effects of dietary fat on the diurnal variation in serum and cerebrospinal fluid (CSF) leptin levels in Osborne‐Mendel (OM) and S5B/Pl rats and quantitate the dose response to lower doses of leptin administered into the third cerebral ventricle. Research Methods and Procedures: Rats were fitted with implanted vascular ports or third ventricular cannulas and fed either laboratory chow or one of two semipurified high‐fat or low‐fat diets. Leptin and insulin were measured by immunoassay. Results: Serum leptin and insulin levels were positively correlated and had similar patterns of diurnal change. CSF leptin and insulin also had diurnal rhythms, with a peak at 7:00 am, but the diurnal oscillations of leptin and insulin were significantly lower in the S5B/Pl rats than the OM rats. Thus, the ratio of CSF to serum leptin was significantly higher in the S5B/Pl rats than in the OM rats. Dietary fat had no effect on these diurnal patterns. There was a right shift in the dose response to leptin in the OM rats compared with the S5B/P1 rats. S5B/P1 rats treated with leptin had higher signal transduction and translation (STAT‐3) mRNA levels compared with pair‐fed or saline injected S5B/P1 rats. Hypothalamic suppressors of cytokine signaling mRNA levels were not statistically different between the groups. Discussion: The higher CSF‐to‐serum leptin ratio in the S5B/P1 rats, the enhanced suppression of food intake and body weight with leptin injections, and the higher STAT‐3 activity in these animals suggest that S5B/P1 rats are more sensitive to leptin than OM rats.     

Effects of Time-of-Day of Hypertension Treatment on Ambulatory Blood Pressure and Clinical Characteristics of Patients With Type 2 Diabetes

Generally, hypertensive patients ingest all their blood pressure (BP)-lowering agents in the morning. However, many published prospective trials have reported clinically meaningful morning-evening, treatment-time differences in BP-lowering efficacy, duration of action, and safety of most classes of hypertension medications, and it was recently documented that routine ingestion of ≥1 hypertension medications at bedtime, compared with ingestion of all of them upon awakening, significantly reduces cardiovascular disease (CVD) events. Non-dipping (<10% decline in asleep relative to awake BP mean), as determined by ambulatory BP monitoring (ABPM), is frequent in diabetes and is associated with increased CVD risk. Here, we investigated the influence of hypertension treatment-time regimen on the circadian BP pattern, degree of BP control, and relevant clinical and analytical parameters of hypertensive patients with type 2 diabetes evaluated by 48-h ABPM. This cross-sectional study involved 2429 such patients (1465 men/964 women), 65.9?±?10.6 (mean?±?SD) yrs of age, enrolled in the Hygia Project, involving primary care centers of northwest Spain and designed to evaluate prospectively CVD risk by ABPM. Among the participants, 1176 were ingesting all BP-lowering medications upon awakening, whereas 1253 patients were ingesting ≥1 medications at bedtime. Among the latter, 336 patients were ingesting all BP-lowering medications at bedtime, whereas 917 were ingesting the full daily dose of some hypertension medications upon awakening and the full dose of others at bedtime. Those ingesting ≥1 medications at bedtime versus those ingesting all medications upon awakening had lower likelihood of metabolic syndrome and chronic kidney disease (CKD); had significantly lower albumin/creatinine ratio, glucose, total cholesterol, and low-density lipoprotein (LDL) cholesterol; and had higher estimated glomerular filtration rate and high-density lipoprotein (HDL) cholesterol. Moreover, patients ingesting all medications at bedtime had lowest fasting glucose, serum creatinine, uric acid, and prevalence of proteinuria and CKD. Ingestion of ≥1 medications at bedtime was also significantly associated with lower asleep systolic (SBP) and diastolic BP (DBP) means than treatment with all medications upon awakening. Sleep-time relative SBP and DBP decline was significantly attenuated in patients ingesting all medications upon awakening (p?<?.001). Thus, the prevalence of non-dipping was significantly higher when all hypertension medications were ingested upon awakening (68.6%) than when ≥1 of them was ingested at bedtime (55.8%; p?<?.001 between groups), and even further attenuated (49.7%) when all of them were ingested at bedtime (p?<?.001). Additionally, prevalence of the riser BP pattern, associated with highest CVD risk, was much greater (23.6%) among patients ingesting all medications upon awakening, compared with those ingesting some (20.0%) or all medications at bedtime (12.2%; p?<?.001 between groups). The latter group also showed significantly higher prevalence of properly controlled ambulatory BP (p <?.001) that was achieved by a significantly lower number of hypertension medications (p?<?.001) compared with patients treated upon awakening. Our findings demonstrate significantly lower asleep SBP mean and attenuated prevalence of a blunted nighttime BP decline, i.e., lower prevalence of markers of CVD risk, and improved metabolic profile in patients with type 2 diabetes ingesting hypertension medications at bedtime than in those ingesting all of them upon awakening. These collective findings indicate that bedtime hypertension treatment, in conjunction with proper patient evaluation by ABPM to corroborate the diagnosis of hypertension and avoid treatment-induced nocturnal hypotension, should be the preferred therapeutic scheme for type 2 diabetes. (Author correspondence: rhermida@uvigo.es)     

Time of day difference in postprandial glucose and insulin responses: Systematic review and meta-analysis of acute postprandial studies

ABSTRACT

Current dietary trends show that humans consume up to 40% of their energy intake during the night. Those who habitually eat during the night are observed to have an increased risk of metabolic conditions such as type-2 diabetes and cardiovascular disease. Increasing evidence suggest that a biological consequence of eating during the night is a larger postprandial glucose response, compared to meals eaten earlier in the day. However, findings from individual acute postprandial studies have been inconsistent, due to variations in protocols. Therefore, this review aimed to systematically summarize findings from acute postprandial studies and investigate whether postprandial glucose and insulin response at night differs to during the day in healthy adults. This would indicate a possible physiological mechanism linking habitual nighttime eating and increased risk of metabolic conditions. Seven electronic databases were searched in February 2018. Included studies met the following criteria: had a day-time test between 0700 – 1600h, a nighttime test between 2000 and 0400h, the test meals were identical and consumed by the same participant at both day and night time points, preceded by a 3-h fast (minimum). Primary outcome measures were postprandial glucose and insulin incremental area under the curve (iAUC) or area under the curve (AUC). Studies that reported numerical data were included in the meta-analyses, conducted using Stata statistical software (version 13.0, StataCorp, College Station, TX, USA). For eligible studies that did not report numerical data, their authors’ conclusions on the effect of time of day on the primary outcome measures were summarized qualitatively. Full text of 172 articles were assessed for eligibility. Fifteen studies met the eligibility criteria, ten of which were included in the meta-analyses. Meta-analysis for glucose showed a lower postprandial glucose response in the day compared to during the night, after an identical meal (SMD = ?1.66; 95% CI, ?1.97 to ?1.36; p < .001). This was supported by the findings from included studies ineligible for meta-analysis. Meta-analysis also showed a lower postprandial insulin response in the day compared to during the night (SMD = ?0.35; 95% CI, ?0.63 to ?0.06; p = .016). However, findings from included studies ineligible for meta-analysis were inconsistent. Our results suggest poor glucose tolerance at night compared to the day. This may be a contributing factor to the increased risk of metabolic diseases observed in those who habitually eat during the night, such as shift workers.     

Circadian Rhythm of Blood Pressure: Internal and External Time Triggers

Diurnal blood pressure (BP) fluctuations are superimposed by a 24-h rhythm with usually lower levels during the night and higher levels during the day. In contrast to other rhythmic bioparameters, the diurnal BP rhythm is largely dependent on activity and sleep rather than on clock time. This has been demonstrated by the BP characteristics after shifted sleeping and working phases, during transition from sleep to wakefulness, and by the influence of sleep and activities on the 24-h BP curve during normal daily routines. Whereas the circadian rhythm of BP is predominantly governed by external time triggers, endogenous rhythmic-ity can only be detected by time microscopic analysis or in conditions where effects of external time triggers are almost excluded.     

Influence of Age and Hypertension Treatment-time on Ambulatory Blood Pressure in Hypertensive Patients

Some studies based on ambulatory blood pressure (BP) monitoring (ABPM) have reported a reduction in sleep-time relative BP decline towards a more non-dipping pattern in the elderly, but rarely have past studies included a proper comparison with younger subjects, and no previous report has evaluated the potential role of hypertension treatment time on nighttime BP regulation in the elderly. Accordingly, we evaluated the influence of age and time-of-day of hypertension treatment on the circadian BP pattern assessed by 48-h ABPM. This cross-sectional study involved 6147 hypertensive patients (3108 men/3039 women), 54.0?±?13.7 (mean?±?SD) yrs of age, with 2137 (978 men/1159 women) being ≥60 yrs of age. At the time of study, 1809 patients were newly diagnosed and untreated, and 4338 were treated with hypertension medications. Among the later, 2641 ingested all their prescribed BP-lowering medications upon awakening, whereas 1697 ingested the full daily dose of ≥1 hypertension medications at bedtime. Diagnosis of hypertension in untreated patients was based on ABPM criteria, specifically an awake systolic (SBP)/diastolic (DBP) BP mean ≥135/85?mm Hg and/or an asleep SBP/DBP mean ≥120/70?mm Hg. Collectively, older in comparison with younger patients were more likely to have diagnoses of microalbuminuria, chronic kidney disease, obstructive sleep apnea, metabolic syndrome, anemia, and/or obesity. In addition, the group of older vs. younger patients had higher glucose, creatinine, uric acid, triglycerides, and fibrinogen, but lower cholesterol, hemoglobin, and estimated glomerular filtration rate. In older compared with younger patients, ambulatory SBP was significantly higher and DBP significantly lower (p?<?.001), mainly during the hours of nighttime sleep and initial hours after morning awakening. The prevalence of non-dipping was significantly higher in older than younger patients (63.1% vs. 41.1%; p?<?.001). The largest difference between the age groups was in the prevalence of a riser BP pattern, i.e., asleep SBP mean greater than awake SBP mean (19.9% vs. 4.9% in older vs. younger patients, respectively; p?<?.001). The sleep-time relative SBP decline was mainly unchanged until ～40 yrs of age, and then significantly and progressively decreasing with increasing age at a rate of .28%/yr (p?<?.001), reaching a minimum value of 4.38%?±?.47% for patients ≥75 yrs of age. Treated compared with untreated patients showed lower awake and asleep SBP means, although the predictable changes of SBP and DBP with age were equivalent in both groups. As a consequence, there were no significant differences between untreated and treated patients in the changes of the sleep-time relative SBP and DBP declines with age. Additionally, the asleep SBP and DBP means were significantly lower and the sleep-time relative SBP and DBP declines significantly higher at all ages in patients ingesting ≥1 BP-lowering medications at bedtime as compared with those ingesting all medications upon awakening. Our findings document a significantly elevated prevalence of a blunted nighttime BP decline with increasing age ≥40 yrs. The prevalence of a riser BP pattern, associated with highest cardiovascular risk among all possible BP patterns, was 4 times more prevalent in patients ≥60 yrs of age than those <60 yr of age. Most important, there was an attenuated prevalence of a blunted nighttime BP decline at all ages when ≥1 hypertension medications were ingested at bedtime as compared with when all of them were ingested upon awakening. These findings indicate that older age should be included among the conditions for which ABPM is recommended for proper cardiovascular risk assessment. (Author correspondence: rhermida@uvigo.es)